Mar 07, 2024
More than 60 current clinical trials are using molecules called F2-isoprostanes (F2-IsoPs) as biomarkers of endogenous oxidative injury. Previous studies have shown that F2-IsoPs are increased in multiple oxidative stress-related diseases, including cardiovascular disease, neurodegeneration, diabetes, certain types of cancer and COVID-19.